These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
206 related articles for article (PubMed ID: 16264773)
1. The impact of epidermal-growth-factor-receptor mutations in response to lung-cancer therapy. Dowell JE; Minna JD Nat Clin Pract Oncol; 2004 Nov; 1(1):2-3. PubMed ID: 16264773 [No Abstract] [Full Text] [Related]
2. EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer. Shih JY; Gow CH; Yang PC N Engl J Med; 2005 Jul; 353(2):207-8. PubMed ID: 16014893 [No Abstract] [Full Text] [Related]
3. Medicine. Why a new cancer drug works well, in some patients. Marx J Science; 2004 Apr; 304(5671):658-9. PubMed ID: 15118127 [No Abstract] [Full Text] [Related]
4. Modern treatment of lung cancer: case 1. Amplification and mutation of the epidermal growth factor receptor in metastatic lung cancer with remission from gefitinib. Schwab R; Pinter F; Moldavy J; Papay J; Strausz J; Kopper L; Keri G; Pap A; Petak I; Oreskovich K; Mangel L J Clin Oncol; 2005 Oct; 23(30):7736-8. PubMed ID: 16234532 [No Abstract] [Full Text] [Related]
5. Unusual cases in multiple myeloma and a dramatic response in metastatic lung cancer: case 4. Mutation of the epidermal growth factor receptor in an elderly man with advanced, gefitinib-responsive, non-small-cell lung cancer. Cho D; Kocher O; Lee JC; Tenen DG; Meyerson ML; Janne PA; Halmos B J Clin Oncol; 2005 Jan; 23(1):235-7. PubMed ID: 15625379 [No Abstract] [Full Text] [Related]
6. Gefitinib. Still no convincing results in non-small cell lung cancer. Prescrire Int; 2010 Jun; 19(107):113. PubMed ID: 20738034 [No Abstract] [Full Text] [Related]
8. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Kosaka T; Yatabe Y; Endoh H; Yoshida K; Hida T; Tsuboi M; Tada H; Kuwano H; Mitsudomi T Clin Cancer Res; 2006 Oct; 12(19):5764-9. PubMed ID: 17020982 [TBL] [Abstract][Full Text] [Related]
9. Supersensitive mutation: two case reports of non-small-cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors. Myerson JS; Iqbal SA; O'Brien ME; Popat S Clin Lung Cancer; 2010 Sep; 11(5):E5-8. PubMed ID: 20837451 [TBL] [Abstract][Full Text] [Related]
10. Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. Jackman DM; Holmes AJ; Lindeman N; Wen PY; Kesari S; Borras AM; Bailey C; de Jong F; Jänne PA; Johnson BE J Clin Oncol; 2006 Sep; 24(27):4517-20. PubMed ID: 16983123 [No Abstract] [Full Text] [Related]
11. Chasing mutations in the epidermal growth factor in lung cancer. Dowell JE; Minna JD N Engl J Med; 2005 Feb; 352(8):830-2. PubMed ID: 15728818 [No Abstract] [Full Text] [Related]
12. Mutations of epidermal growth factor receptor of non-small cell lung cancer were associated with sensitivity to gefitinib in recurrence after surgery. Kondo M; Yokoyama T; Fukui T; Yoshioka H; Yokoi K; Nagasaka T; Imaizumi K; Kume H; Hasegawa Y; Shimokata K; Sekido Y Lung Cancer; 2005 Dec; 50(3):385-91. PubMed ID: 16140420 [TBL] [Abstract][Full Text] [Related]
13. Pharmacogenomics. Cancer sharpshooters rely on DNA tests for a better aim. Couzin J Science; 2004 Aug; 305(5688):1222-3. PubMed ID: 15333809 [No Abstract] [Full Text] [Related]
14. Lack of response to erlotinib after progression on gefitinib in patients with advanced non-small cell lung cancer. Viswanathan A; Pillot G; Govindan R Lung Cancer; 2005 Dec; 50(3):417-8. PubMed ID: 16129510 [No Abstract] [Full Text] [Related]
15. Intron 1 CA dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and gefitinib responsiveness in non-small-cell lung cancer. Han SW; Jeon YK; Lee KH; Keam B; Hwang PG; Oh DY; Lee SH; Kim DW; Im SA; Chung DH; Heo DS; Bang YJ; Kim TY Pharmacogenet Genomics; 2007 May; 17(5):313-9. PubMed ID: 17429313 [TBL] [Abstract][Full Text] [Related]
16. Mutations in the epidermal growth factor receptor gene in non-small cell lung cancer: Impact on treatment beyond gefitinib and erlotinib. Heigener DF; Reck M Adv Ther; 2011 Feb; 28(2):126-33. PubMed ID: 21181318 [TBL] [Abstract][Full Text] [Related]
17. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Huang SF; Liu HP; Li LH; Ku YC; Fu YN; Tsai HY; Chen YT; Lin YF; Chang WC; Kuo HP; Wu YC; Chen YR; Tsai SF Clin Cancer Res; 2004 Dec; 10(24):8195-203. PubMed ID: 15623594 [TBL] [Abstract][Full Text] [Related]
18. Implications of the Iressa Survival Evaluation in Lung Cancer trial and the future of gefitinib. Belani CP; Ramalingam S Clin Lung Cancer; 2005 Jan; 6(4):203-4. PubMed ID: 15694010 [No Abstract] [Full Text] [Related]
19. Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer. Mu XL; Li LY; Zhang XT; Wang MZ; Feng RE; Cui QC; Zhou HS; Guo BQ Clin Cancer Res; 2005 Jun; 11(12):4289-94. PubMed ID: 15958609 [TBL] [Abstract][Full Text] [Related]
20. Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors. Haber DA; Bell DW; Sordella R; Kwak EL; Godin-Heymann N; Sharma SV; Lynch TJ; Settleman J Cold Spring Harb Symp Quant Biol; 2005; 70():419-26. PubMed ID: 16869779 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]